The antiarrhythmic efficacy and safety of oral encainide hydrochloride and quinidine sulfate were compared in a nine center double-blind crossover study in 187 out• patients with benign or potentially lethal ventricular ar• rhythmias. Patients with at least 30 premature ventric• ular complexes/Ii were randomized to receive either encainide, 25 mg four times/day, or quinidine, 200 mg four times/day, for :z weeks. These doses were continued for another 2 weeks if a, 75% or greater reduction in premature ventricular compiexes was observed. If this reduction was not seen, encainide was increased to 50 mg four times/day or quinidine to 400 mg four times/day for an additional 2 weeks.
The antiarrhythmic efficacy and safety of oral encainide hydrochloride and quinidine sulfate were compared in a nine center double-blind crossover study in 187 out• patients with benign or potentially lethal ventricular ar• rhythmias. Patients with at least 30 premature ventric• ular complexes/Ii were randomized to receive either encainide, 25 mg four times/day, or quinidine, 200 mg four times/day, for :z weeks. These doses were continued for another 2 weeks if a, 75% or greater reduction in premature ventricular compiexes was observed. If this reduction was not seen, encainide was increased to 50 mg four times/day or quinidine to 400 mg four times/day for an additional 2 weeks.
Both drugs produced a statistically significant reduc• tion in premature ventriCUlar complex frequency com• pare(l with baseline values. Encainide produced a sta• tistically significant greater mean reduction in total premature ventricular complexes than did quinidine during the initial dose phase and after dose adjustment. More patients required dose iitcreases of quinidine (60%) than of encainide (51 %). Early discontinuation of treatEvidence is mounting that sudden cardiac death is due to ventricular tachyarrhythmias iri most patients (1) and that the patient at high risk for such an event can be identified by the presence of premature ventricular complexes and left ventricular dysfunction (2, 3) . A search for more effective and better tolerated antiarrhythmic agents has been under• way for use in studies designed to test whether sudden cardiac death can be prevented by elimination of such ar• rhythmias (2, 4) , Quinidine is the oldest and the most widely creased significantly during encainide treatment, as did QTc and JT intervals during quinidine treatment. No adverse reactions resulted from these electrocardio• graphic changes.
Adverse reactions were more ~ommon with quinidine than with encainide. A proarrhythmic effect was noted in eight patients taking encainide (five had an increase in premature ventricular complex frequency and three an increase in the duration of asymptomatic ventricular tachycardia) and in four patients taking quinidine (one had an increase in premature ventricular complex fre• quency and two an increase in the duration of asymp• tomatic ventricular tachycardia; and syncope developed . in one) (p = NS). Thus, encainide appears to be more effective and has fewer sidE! effects than quinidine and may be a reasonable alternative to quinidine therapy for ventricular arrhythmias.
(J Am Coli CardioI1986; 7:9-16) prescribed antiarrhythmic agent in the United States (5) and studies (2,5-7) have established its effectiveness and safety in approximately 60 to 80% of patients with benign and potentially lethal ventricular arrhythmias.
Encaihide is a potent new class Ie antiarrhythmic agent (2) . It lengthens intraatrial, atrioventricular (A V) node, His• Purkinje and intraventricular conduction (8) . It has no sig• nificant negative inotropic effect (9) and thus may be val• uable in patients with severe left ventricular dysfunction who benefit most from control of ventricular arrhythmias. Placebo-controlled studies using appropriate standards (10) have demonstrated that encainide is effective in 70 to 80% of patients with ventricular arrhythmias. The effective dose appears to be between 25 and 50 mg three to four times/day (11) (12) (13) . Aggravation of arrhythmias (proarrhythmia) from encainide has been previously reported in approximately 10% of patients with benign and potentially lethal ventric-ular arrhythmias (11) (12) (13) . Patients with more lethal arrhyth• mias and more severe degrees of left ventricular dysfunction have a higher incidence of proarrhythmic events (14, 15) . Our study was designed to compare the safety and efficacy of encainide and quinidine with emphasis on the safety of initiating each agent in outpatients with benign or potentially lethal ventricular arrythmias.
Methods
Patient selection. Nine clinical centers enrolled patients 18 years or older who demonstrated at least 30 premature ventricular complexes/h on a 24 hour Holter monitor re• cording taken near the end of 1 week of placebo therapy (baseline). The initial placebo period was preceded by a 1 week washout period in which all prior antiarrhythmic ther• apy was discontinued and a qualifying Holter monitor re• cording was obtained to determine eligibility. Patients were included in the study only if their ventricular arrhythmias required therapy in the judgment of the investigator. Patients were excluded if they had hemodynamically significant, severe, life-threatening ventricular arrhythmias (4) or a his• tory of severe intolerance or allergic reaction to either en-JACC Vol. 7, No.1 January 1986: [9] [10] [11] [12] [13] [14] [15] [16] cainide or quinidine. Patients were also excluded if they had evidence of sick sinus syndrome, required the presence of a pacemaker, had a baseline QRS duration of more than 0.14 second, a PR interval of more than 0.24 second or a QTc interval of more than 0.50 second. Uncontrolled hy• pertension, congestive heart failure, angina pectoris, seizure disorders, abuse of alcohol or significant renal or hepatic failure were other criteria for exclusion from the study. Patients with evidence of acute myocardial infarction or use of amiodarone within 90 days before enrollment were also excluded. Protocol (Table 1 ). This was a multicenter, 14 week, double-blind, randomized, crossover comparative study of encainide versus quinidine in outpatients. It included six consecutive periods: 1) washout; 2) initial placebo; 3) first active drug; 4) second placebo; 5) second active drug; and 6) final placebo. After the initial 7 day washout period, patients qualifying (those with premature ventricular com• plexes averaging 2:30/h) on the first 24 hour Holter monitor recording received placebo for 1 week and underwent a second Holter recording. Eligible patients were then entered into the first active drug period to receive either encainide or quinidine for 4 weeks. At the end of 2 weeks, the dose of active medication could be increased if a 75o/c reduction in premature ventricular complex frequency compared with the initial placebo period had not been obtained. A two week second placebo period followed the first active drug period. During this second placebo penod a reappearance of at least 50% of the baseline premature ventricular com~ plex frequency was required for continuatIOn In the study Patients eligible to contmue received the alternate medi• cation in the second active period in a manner identical to that of the first active drug period. The study ended with a 2 week final placebo penod in which a 24 hour Holter recording was obtained.
All placebo and active drug formulatIOns were identical in appearance and were prepackaged, labeled and provided in individual dose packets. The quinidine capsules used in the study were bioequivalent to commercially available quinidine sulfate capsules (Eli Lilly, USP, Pulvule No. 239). The initial dose of encainide was 25 mg four times/day and the adjusted dose was 50 mg four times/day. The initial dose of quinidine sulfate was 200 mg four times/day and the adjusted dose was 400 mg four times/day. Any patient who had an adverse reaction requiring discontinuation of the active agent was entered directly into the next period of the protocol or withdrawn from the study. The protocol was reviewed and approved by each center's institutional review board, and all patients were required to give written in• formed consent before entering the study.
Data analysis. The primary criterion for efficacy was a 75% reduction from baseline value in the average hourly premature ventricular complex frequency as determined by 24 hour Holter recordings. The baseline for the first active drug period was the initial placebo period (the second week of study) and the baseline for the second active drug period was the second placebo period. Additional comparisons were made of the percent suppression of paired premature ven• tricular complexes (couplets) and premature ventricular complexes occurring in runs of three or more (ventricular tachycardia). Evaluations of drug safety included measure• ments of vital signs, electrocardiogram~, clinical laboratory tests, physical examinations, reports of conditions during therapy and proarrhythmia assessment~ <Table I)
The criterion for dejinm~ a proarrhythm/c event (16) was the appearance at any time during the active drug penod of the study of a more severe ventricular arrhythmia than had been previously documented. An increase in the hourly av• erage of premature ventricular complex frequency over that of the initial placebo arrhythmia baseline frequency was also used (16) . Unexplained syncope was a)<;o considered a pro arrhythmic response in this analYSIS,
The Holter monitor tapes were analy:ed by an indepen• dent research facility (Cardio-Data Systems of United Med• ical Corporation) using a complete computer-generated re• port for each tape analyzed. To ensure accuracy, a quality control program was performed using hand-counted, 24 hour MORGAN ROTH ET AL ENCAINlDE VERSUS QUINIDINE FOR ARRHYTHMIAS 11 Holter tapes randomly inserted into the system. In addition, to ensure reproducibility, the same tapes were repeatedly analyzed at different times. Precise quantitation of the fre• quency of premature ventricular complexes, couplets and beats of ventricular tachycardia were performed. Validation of this method has been reported previously (6) . To reduce the right skewness of their distribution, the hourly rates of total premature ventricular complexes, couplets and beats of ventricular tachycardia were transformed by adding one and taking the natural logarithm before computing the change from the appropriate placebo baseline study.
Statistics. A linear model of analysis of variance was used on data from patients who completed both active drug periods to determine whether data from all study centers could be pooled for analysis of efficacy and to compare the efficacy of the two agents. Another linear model was also used to analyze data from all patients who completed the first active drug periods.
Results
Patient characteristics. There were 187 patients ran• domized at the nine study centers. The mean age of the 187 patients was 60 years (range 26 to 86) and 76 (41%) were 65 years of age or older; 133 (71 %) were male and 152 (81 %) were white. One hundred seventy-three patients com• pleted the first active drug period and 134 (72%) completed both active drug periods (Table 2) . Ninety-five patients were randomized to the encainide-quinidine sequence and 92 to the quinidine-encainide sequence. Of the 187 patients, 154 (82%) had received a total of 384 prior antiarrhythmic treat• ments. Seventy-three percent of these prior treatments were discontinued because of inadequate efficacy or side effects, or both, Fifty-six (30%) of the 187 patients randomized to this trial did not complete all 6 periods of the study. Five patients discontinued the study because of conditions during therapy and five others because of intercurrent illness. Four addi• tional patients died during the study (two taking placebo and two taking encainide). Other reasons for not completing the study trial were: administrative problems (n = 7 patients
[4%]); patient noncompliance (n = 6 [3% l); patient lost to follow-up (n = 1); insufficient premature ventricular com• plex frequency during the first placebo period (second week of study) (n = 6 [3%]) and insufficient premature ventricular complex return during the second placebo period (n = 21
[ I 1 % J). One additional patient discontinued therapy because his prior physician prescribed another antiarrhythmic med• ication, Of the 56 patients who did not complete the study trial, 29 had been assigned to the encainide then quinidine sequence, and 27 to the quinidine then encainide sequence. One hundred seventy-three (93%) of the patients received concomitant medications, which included cardiac glyco• sides in 42 (22%), diuretic drugs in 58 (31 %), coronary After dose adjustment, fewer patients had events of ven• tricular tachycardia but the difference between encainide and quinidine was no longer statistically significant. Figure  3 shows the percent of patients who responded to active drug treatment with a 75% or greater reduction in total ....
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• Qui Figure 3 . Percent of patients responding at 75% or greater re• duction in total premature ventricular complexes/h is demonstrated for encainide (Enc) and quinidine (Qui) during initial dose (phase I) and adjusted dose (phase II) periods in the trial. The dagger indicates a significant difference between encainide and quinidine using Fisher's exact test at the 5% level.
premature ventricular complexes, During the initial dosing period a greater percent of patients responded to encainide than to quinidine (p < 0.05). However, the difference be• tween the two drugs was no longer statistically significant after dose adjustment. During initial dosing, 81% of the patients had a 75% reduction from baseline in ventricular tachycardia beats per hour with encainide treatment com• pared with a 60% reduction with quinidine treatment (p < 0.05). After dose adjustment, 84% of the patients taking encainide responded compared with 78% of those taking quinidine (p == NS).
Of the 153 patients who received encainide in this study, 106 (79%) continued in a long-term encainide follow-up study. There was no significant difference in the response to encainide or quinidine treatment with regard to sex, race, New York Heart Association functional class, previous his• tory of ventricular tachycardia, congestive heart failure or myocardial infarction, baseline conduction abnormality or baseline frequency of premature ventricular complexes. In MORGANROTH ET AL.
ENCAINIDE VERSUS QUINIDINE FOR ARRHYTHMIAS
patients younger than 65 years of age, there was a statis• tically significant greater reduction in premature ventricular complex frequency during encainide than during quinidine treatment, whereas in patients older than 65 years of age, quinidine and encainide similarly reduced total premature ventricular complex frequency.
Safety. Five patients were withdrawn prematurely from the study because of intercurrent illness and five others because of conditions during therapy (four receiving placebo and one receiving quinidine). Conditions during therapy were reported in 159 (85%) of 187 patients during placebo or active drug treatment periods, or both. Seventy-five per• cent of the patients (114 of 153) taking encainide had 281 on-therapy conditions whereas 80% (123 of 154) of the patients taking quinidine had 407 on-therapy conditions. Table 3 details the relative side effects observed. Side effects that required early discontinuation of an active drug and advancement into the next placebo period occurred in 12 patients taking encainide as compared with 38 patients taking quinidine (p < 0.001). Of the 12 patients who dis• continued encainide and advanced to the next phase, 6 stopped during the initial dose phase and 6 soon after the dose had been increased. Discontinuations during encainide therapy were for side effects primarily related to the central nervous system (for example, visual disturbances and dizziness). Of the 38 patients who discontinued quinidine treatment and advanced to the next study period, 27 stopped during initial dosing and 11 soon after the dose increase. Most of the side effects from quinidine were related to the gastrointestinal system and were primarily diarrhea and nausea. Only five patients were withdrawn from the study because of on• therapy conditions other than intercurrent illness. One pa• tient was withdrawn because of diaphoresis and vomiting during the first placebo period, two (one because of nausea and worsening congestive heart failure and one because of malaise and abdominal numbness) during the second pla• cebo period, one because of an altered level of consciousness on quinidine and one because of nausea and frequent pre• mature ventricular complexes during the final placebo pe• riod. All three patients who discontinued therapy during the second and final placebo periods were taking quinidine. More patients receiving quinidine than those receiving encainide had fever (12 versus 0), malaise (6 versus 0) and diarrhea (60 versus 14). Headache occurred in 9% of patients receiving encainide compared with 16% of those receiving quinidine. Conversely, dizziness occurred in 16% of pa• tients taking encainide versus 15% of those taking quinidine, and blurred vision in 9% taking encainide compared with 6% taking quinidine (p = NS). Five patients had on-therapy conditions suggesting exacerbation of congestive heart fail• ure, one patient receiving both encainide and quinidine and two patients receiving either encainide or quinidine. In three of these five patients no action was taken, in one furosemide was increased and in the remaining patient anti-ischemic therapy was increased.
EtTects on electrocardiographic intervals and other measures (Table 4) . Dose-related increases in electrocar• diographic intervals followed the use of both encainide and quinidine. PR and QRS intervals were increased during encainide therapy, whereas the QTc and JT intervals were increased during quinidine therapy. Five patients taking en• cainide had an increase in PR interval to 0.28 to 0.44 second and three patients had an increase in QRS interval to 0.20 to 0.24 second. No patient developed second or third degree heart block or obvious clinical change in baseline medical condition due to changes in PR and QRS intervals.
No clinically significant changes in blood pressure and heart rate were noted in this study and there was no obvious relation of any changes in laboratory test with an active drug regimen that was clinically significant.
Proarrhythmic etTects. Twelve patients met the study criteria for proarrhythmia during this trial. In eight patients proarrhythmia was noted during encainide therapy. In five, an increase in premature ventricular complex frequency was documented and in three the occurrence of an II, 27 and 13 beat run of asymptomatic ventricular tachycardia was noted. In four patients taking quinidine, proarrhythmia was noted. One of the four had an increase in premature ven• tricular complex frequency, two had a 12 beat run of asymp• tomatic ventricular tachycardia and one had an unexplained loss of consciousness for 20 minutes with presyncopal symp• toms. This patient did not have an objective documentation of proarrhythmia, but is included because this possibility could not be excluded. One patient had an increase in pre• mature ventricular complex frequency defined as proar• rhythmia while receiving both encainide and quinidine. In one patient each taking quinidine and encainide with a 12 and 13 beat run of ventricular tachycardia, respectively, these events disappeared when the patient began taking the higher dose of the drug. No patient had hemodynamic symp• toms from the change in premature ventricular complex frequency or the number of beats in ventricular tachycardia events and no patient was withdrawn prematurely from ther• apy because of these episodes.
Four patients died in this trial; two had been receiving encainide, one was in the first placebo period and one was in the second placebo period after quinidine treatment. One patient died after 7 days of treatment with encainide, 25 mg four times/day, probably because of a new myocardial in• farction with coronary artery bypass graft closure. The sec• ond patient also died after 7 days of receiving encainide, 25 mg four times/day. She had a recent exacerbation of angina pectoris and had severe nocturnal anginal episodes during the first placebo period. It was believed that her death was not related to encainide. A death of a patient due to ventricular fibrillation after 7 days of placebo following 27 days of quinidine dosing was notable in that while receiving quinidine he complained of shortness of breath and pul• monary congestion and had a 5 pound (2.25 kg) weight gain. Another death after 2 days of taking predrug placebo was possibly due to an arrhythmia.
Encainide and digoxin interaction. Serum digoxin lev• els were measured in 21 patients (Table 1) . During encainide treatment there was no statistically significant difference in serum digoxin levels between baseline and encainide treat• ment (range 0.5 to 2.1 versus 0.3 to 2.2 ng/ml, respectively) or between the two encainide dose levels. During quinidine therapy, there was a statistically significant dose-related in• crease in serum digoxin levels (p < 0.01). 
Discussion
This multicenter, double-blind, crossover trial compared oral encainide (25 to 50 mg four times/day) with oral quin• idine (200 to 400 mg four times/day) in the treatment of benign and potentially lethal ventricular arrhythmias. Quin• idine was chosen as the comparative agent because of its common use in the United States and its common reference status when studying new antiarrhythmic drugs. The results of this study reveal that encainide and quinidine each produced a statistically significant reduction in total premature ven• tricular complex frequency when compared with baseline values; encainide produced a greater reduction than did quin• idine during both the initial dose and adjusted higher dose treatment. Suppression of ventricular tachycardia was also significantly better during encainide than during quinidine therapy in the initial dose period, although this difference was no longer significant after dose adjustment. More pa• tients required an increase in the dose of quinidine (60%) than of encainide (51 % ) .
These results are comparable with those in a study by Sami et al. (17) , which was a longitudinal, crossover, com• parative study using a fixed dose of quinidine and encainide in 20 men over 8 weeks. Encainide at 50 mg four times/day suppressed all premature ventricular complexes in 44% of the patients and reduced the frequency by 80% or more in 88% of the patients. When ventricular tachycardia beats were present, 100% reduction resulted in all patients. Quin• idine at a dose of 300 mg four times/day did not totally suppress premature ventricular complexes in any patient and resulted in an 80% reduction in such complexes in less than 50% of the patients. In only 50% of the patients was there complete suppression of ventricular tachycardia. This mul• ticenter study confirms these preliminary data in patients who have a higher frequency of ventricular arrhythmia, using two different drug dosing levels and more frequent Holter monitoring.
Drug tolerance. Encainide was better tolerated in this study than was quinidine. The prevalence and nature of side effects are similar to those reported from previous studies (5, 6, (11) (12) (13) . The common side effects noted with encainide therapy were dizziness and blurred vision, whereas the prominent side effects with quinidine were gastrointestinal symptoms and fever. Encainide increased the PR and QRS intervals in a manner with its electrophysiologic effects (8) . None of these changes required discontinuation of the drug nor did second or third degree heart block occur. We, there• fore, have suggested that patients cont~nue receiving en• cainide despite changes in the PR and QRS intervals up to 0.28 and 0.18 second, respectively. There was no evidence that any electrocardiographic change in this study was re• lated to side effects or new symptoms.
Recommendations. Neither drug in the doses used caused changes of clinical significance in vital signs or laboratory variables. Proarrhythmic effects were documented in terms of exacerbation of the frequency of premature ventricular complexes or the number of beats in a ventricular tachy• cardia event. None of these proarrhythmic events resulted in hemodynamic consequences and, therefore, we believe that encainide and quinidine can be safely initiated in an outpatient setting in patients with benign or potentially lethal ventricular arrhythmias. These results are similar to those seen when comparing quinidine with flecainide, another class Ie antiarrhythmic agent (6) . That study also found no hemodynamically significant proarrhythmic event from out• patient initiation of flecainide or quinidine. However, the use of encainide or flecainide in patients with lethal ven• tricular arrhythmias (2) requires more caution, including inhospital monitoring, slow dose escalation schedule and avoidance of high doses (for example, >200 mg/day of encainide) to maximize safety (15, 16) .
Thus, encainide appears to be more effective than quin• idine (at the doses used in this study) with fewer side effects and may be a reasonable alternative to quinidine therapy for benign and potentially lethal ventricular arrhythmias.
